

CURRICULUM VITAE

Roman Shrestha, PhD, MPH

University of Connecticut
College of Agriculture, Health, and Natural Resources
Department of Allied Health Sciences
358 Mansfield Rd. U-1101
Storrs, CT 06269
E-mail: roman.shrestha@uconn.edu
Website: <https://rshresthalab.com/>

EDUCATION AND TRAINING

- 2018-2019 **Postdoctoral Fellow**
AIDS Program, Yale University
- 2017-2018 **Postdoctoral Research Associate**
Institute for Collaboration on Health, Intervention, and Policy, UConn
- 2013-2017 **PhD, Public Health**
Department of Public Health Sciences, UConn
Dissertation: “*Developing and testing an integrated, brief bio-behavioral HIV prevention intervention targeting high-risk drugs users in treatment*”
- Awarded the ‘**Outstanding Dissertation Award 2018**’ and the ‘**Optimization of Behavioral & Biobehavioral Interventions Research Award**’ by the Society of Behavioral Medicine
- 2011-2013 **MPH, Public Health**
University of Connecticut
Thesis: “*Understanding HIV risk behaviors among migrant workers in Nepal*”
- 2007-2011 **BS, Biology (*Summa cum laude*)**
Wiley College

ACADEMIC AND RESEARCH APPOINTMENTS

- 2021- **Assistant Professor**
Allied Health Sciences, University of Connecticut
- 2021- **Principal Investigator**
Institute for Collaboration on Health, Intervention, & Policy, University of Connecticut
- 2021- **Assistant Professor Adjunct**
AIDS Program, Department of Internal Medicine, Yale School of Medicine
- 2019- **Visiting Senior Lecturer**
Centre of Excellence for Research in AIDS (CERiA), University of Malaya

- 2019-2020 **Associate Research Scientist (Faculty)**
AIDS Program, Department of Internal Medicine, Yale School of Medicine
- 2018- **Research Affiliate**
Center for Interdisciplinary Research on AIDS, Yale University
- 2015-2017 **Teaching Assistant**
Department of Allied Health Sciences, University of Connecticut
- 2015-2016 **Instructor**
Department of Allied Health Sciences, University of Connecticut
- 2012-2018 **Research Assistant**
University of Connecticut
Project: *Secondary HIV Prevention and Adherence Among HIV-infected Drug Users* (National Institute on Drug Abuse; R01DA032290, PI Copenhaver)
- 2011-2012 **Research Assistant**
University of Connecticut
Project: *Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users* (National Institute on Drug Abuse; R01DA022122, PI Copenhaver)
- 2009-2011 **Research Intern**
CT-RI Public Health Training Center Program, UConn Health Center
- 2009-2011 **Academic Tutor**
Student Support Services, Wiley College

GRANTS

Ongoing

- 2020-2025 **Principal Investigator** \$765,496
Training in mHealth Prevention with MSM
National Institute on Drug Abuse, K01DA051346
- 2020-2025 **Principal Investigator** \$1,319,241
Development and testing of a mobile app to enhance HIV prevention cascade in Malaysian MSM
Fogarty International Center, R21TW011665 (R21/R33)
- 2020-2022 **Principal Investigator** \$460,625
Integrated rapid access to HIV prevention program for people who inject drugs (iRaPID)
National Institute on Drug Abuse, R21DA051934

2021-2023	Principal Investigator (Wickersham & Shrestha, MPI) <i>Improving HIV testing and PrEP for transgender women through mHealth</i> National Institute of Allergy and Infectious Diseases, R21AI157857	\$460,625
2019-2022	Principal Investigator <i>Expanding Pre-Exposure Prophylaxis (PrEP) Implementation in Communities of People Who Inject Drugs and Their Risk Network Members</i> Gilead Investigator Sponsored Research, IN-US-412-5629	\$522,126
2021-2023	Principal Investigator <i>Integrated rapid access to HIV prevention program for people who inject drugs</i> Gilead Research Scholar Program in HIV, Gilead Sciences	\$130,000
2018-2022	Co-Investigator (PI UConn Subaward) <i>Methadone vs. Buprenorphine Therapy for Opioid Dependence: Diet and Metabolic Implications</i> Rutgers University Busch Biomedical Grant Program (PI Rawal)	\$39,935
2020-2022	Consultant <i>Developing an Artificial Intelligence Chatbot to Promote HIV Testing</i> National Institute of Allergy and Infectious Diseases, R21AI152937 (PI Wickersham)	
2020-2022	Consultant <i>Developing an Artificial Intelligence-Based mHealth Intervention to Increase HIV Testing in Malaysia</i> Fogarty International Center, R21TW011663 (MPI Ni & Altice)	
<i>Under Review</i>		
2022-2025	Principal Investigator (Shrestha & Wickersham, MPI) <i>Integrated online-to-offline (O2O) model of care for HIV prevention and treatment among men who have sex with men</i> National Institute of Mental Health, R34	\$717,145
2021-2026	Co- Investigator <i>Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP</i> National Institute on Drug Abuse, R01 (PI Copenhaver)	
2022-2024	Consultant (JIT Submitted) <i>Gamification to enhance engagement in HIV prevention and co-morbid conditions in young men who have sex with men</i> National Institute of Mental Health, R21 (PI Wickersham)	
2022-2024	Consultant (JIT Submitted) <i>Strengthening the HIV care continuum for transgender women living with HIV in Malaysia</i> National Institute of Mental Health, R21 (PI Wickersham)	

Completed

2019-2021	Co-Investigator (PI UConn Subaward) <i>Examining Ethical Concerns in the Context of App-Based HIV Prevention Research with Men who have Sex with Men in the Malaysian Context</i> National Institute on Drug Abuse, R25DA031608 (PI Fisher)	\$25,000
2018-2020	Principal Investigator <i>Theory-based approach to pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Malaysia</i> Yale Lesbian, Gay, Bisexual, and Transgender Studies	\$5,000
2016-2018	Principal Investigator <i>Integrated bio-behavioral HIV prevention intervention targeting PWID</i> Institute for Collaboration on Health, Intervention, & Policy (InCHIP) Seed Grant, University of Connecticut	\$2,000
2014-2016	Principal Investigator <i>Developing an evidence-based intervention targeting high-risk migrant workers</i> InCHIP Seed Grant, University of Connecticut	\$2,000
2011-2013	Principal Investigator <i>HIV-related risk behaviors among returnee male migrant workers in Nepal</i> College on Liberal Arts and Sciences (CLAS) Research Grant, UConn	\$1,500

Unfunded

2020-2025	Co-Investigator (At Yale) <i>Developing optimal primary HIV prevention among non-treatment seeking opioid-dependent persons</i> National Institute on Drug Abuse, R01 (PI Copenhaver)	(Subaward) \$460,332
2021-2023	Consultant <i>An interactive mHealth app to promote HIV self-testing among men who have sex with men in Vietnam</i> National Institute of Mental Health, R21 (PI Ha)	
2021-2026	Consultant <i>Development and testing of an app-based smoking cessation intervention for people living with HIV</i> National Institute on Drug Abuse, R21/R33 (PI Poudel)	
2021-2023	Consultant <i>Strengthening HIV care continuum for transgender women living with HIV in Malaysia</i> National Institute of Mental Health, R21 (PI Wickersham)	

FELLOWSHIPS, HONORS, AND ACADEMIC RECOGNITION

2022	Faculty & Multidisciplinary Advisory Committee, Fordham HIV and Drug
------	---

- 2021 Prevention Research Ethics Training Institute, Funded by NIDA
Gilead Research Scholar Program Award, Gilead Sciences
- 2021 **Summer Institute on Just-in-Time Adaptive Interventions**, Funded by the National Institute on Drug Abuse (NIDA)
- 2020 **Travel Award**, 12th International Women's and Children's Health and Gender (InWomen's) Group
- 2019 **Fellow**, Fordham HIV and Drug Prevention Research Ethics Training Institute, Funded by the National Institute on Drug Abuse (NIDA)
- 2019 **Fellow, Training on Optimization of Behavioral & Biobehavioral Interventions**, Funded by the Office of Behavioral & Social Science Research (OBSSR)/NIDA
- 2019 **Travel Award**, 11th International Women's and Children's Health and Gender (InWomen's) Group
- 2018 **International Conference on Stigma Scholarship**, Howard University
- 2018 **Ending Gender Inequalities Conference Travel Award**, RTI International
- 2018 **Alumni Inductee**, Delta Omega National Public Health Honor Society
- 2018 **Outstanding Dissertation Award**, Society of Behavioral Medicine (SBM)
- 2018 **Optimization of Behavioral & Biobehavioral Interventions Research Award**, Society of Behavioral Medicine (SBM)
- 2017 **Top Reviewer in Medicine – 2017**, Publons Peer Review Awards 2017
- 2016 **COMPACT for Faculty Diversity Travel Award**, Graduate School (University of Connecticut)
- 2016 **Travel Award for Early Career Investigators**, College on Problems of Drug Dependence (CPDD)
- 2016 **Ending Gender Inequalities Conference Travel Award**, RTI International
- 2015 **NIDA Women and Sex/Gender Differences Junior Investigator Travel Award**, National Institute on Drug Abuse
- 2015 **Doctoral Student Travel Award**, Graduate School (University of Connecticut)
- 2011-2012 **Predocorial Fellowship**, University of Connecticut
- 2007-2011 **Presidential Scholarship**, Wiley College
- 2011 **Allen Mercer Mayes & Laverne Hadnott Mayes Endowed Scholarship**, University of Rhode Island
- 2010 **Destination Public Health Travel Award**, Rollins School of Public Health (Emory University)
- 2010 **Who's Who Among Students in American Universities & Colleges**, USA
- 2007 **International Student Award**, Wiley College
- 2004-2005 **Mahatma Gandhi Scholarship**, Indian Embassy, Nepal
- 2004 **Presidential Scholarship**, Ambition Academy, Nepal

PROFESSIONAL SERVICES

Grant Reviewing

- 2022 **National Institute of Health**, March 2022, Ad hoc reviewer; NIH Center for Scientific Review (CSR); Risk, Prevention and Health Behavior (RPHB) Integrated Review Group Special Emphasis Panel
- 2021 **National Institute of Health**, December 2021, Ad hoc reviewer; NIH Center for

- 2021 Scientific Review (CSR); Risk, Prevention and Health Behavior (RPHB)
Integrated Review Group Special Emphasis Panel
National Institute of Health, April 2021, Ad hoc reviewer; NIH Center for
Scientific Review (CSR); Risk, Prevention and Health Behavior (RPHB)
Integrated Review Group Special Emphasis Panel
- 2021 **University of Washington/Fred Hutch Center for AIDS Research (CFAR)**
New Investigator Awards Grant reviewer
- 2021 **Institute for Collaboration on Health, Intervention, and Policy**
Graduate Student Seed Grant reviewer
- 2020 **Centers for Disease Control and Prevention** for *Special Emphasis Panel*
Review: PS21-001
- 2020 **Centers for Disease Control and Prevention** for *Special Emphasis Panel*
Review: PS20-001
- 2017 **National Science Centre Reviewer** (Poland) for *SONATA (Early career award)*
- 2015 **Institute for Collaboration on Health, Intervention, and Policy**
Graduate Student Seed Grant reviewer

Journal Service

- 2021- **Associate Editor** for *Frontiers in Public Health*
- 2020-Current **Associate Editor** for *Contemporary Clinical Trials*
- 2018-Current **Consulting Editor** for *AIDS & Behavior*
- 2017-2020 **Associate Editor** for *BMC Women's Health*
- 2017-2019 **Associate Editor** for *BMC Public Health*
- 2015-Current **Reviewer** for *Journal of the International AIDS Society; American Journal of Public Health; and Alcohol Dependence; Journal of Acquired Immune Deficiency Syndromes; Addictive Behaviors; AIDS & Behavior; BMJ Open; AIDS Care; Clinical Epidemiology; Medicine; Contemporary Clinical Trials; Journal of Substance Abuse Treatment; International Journal of STD & AIDS; BMC Public Health; Journal of the International Association of Providers of AIDS Care; Frontiers in Public Health; Health and Quality of Life Outcomes; Journal of Medical Internet Research; LGBT Health; International Social Work; Patient Preference and Adherence; Journal of Immigrant and Minority Health; Substance Abuse: Research & Treatment; PLoS ONE; JMIR mHealth and uHealth; BMC Women's Health; Journal of HIV/AIDS & Social Services; Substance Abuse and Rehabilitation; HIV/AIDS - Research and Palliative Care; Tobacco Use Insights*

Professional Organizations

- 2016-Present Member, International AIDS Society (IAS)
- 2021-Present Member, College on Problems of Drug Dependence (CPDD)
- 2015-Present Member, Society for Behavioral Medicine (SBM)
- 2012-Present Member, American Public Health Association (APHA)
- 2012-2017 Member, Connecticut Public Health Association (CPHA)
- 2012-2017 Member, Public Health Student Organization (PHSO), UConn Health Center

Additional Services

- 2020-2021 **AIDS 2020 International Scholarship Application Reviewer Committee,**

- 2019 International AIDS Society (IAS)
2019 Multiple Health Behavior Change SIG Student Award Search Committee, Society for Behavioral Medicine (SBM)
- 2018 **Outstanding Trainee Abstract in Health Decision Making Search Committee**, Society for Behavioral Medicine (SBM)
- 2018-2020 **IAS Conference – Abstract Mentor**, International AIDS Society (IAS)
- 2017 **Co-Liaison**, Violence & Trauma Special Interest Group, Society of Behavioral Medicine (SBM)
- 2017 **Oral Session Moderator**, 2017 American Public Health Association Annual Conference
 - HIV and Substance Use
 - HIV Prevention in Injection Drug Users
- 2011-2012 **Website Committee Chair**, Student Assembly, American Public Health Association (APHA)

PUBLICATIONS

Book Chapters

(*denotes current/former undergraduate/graduate student or mentee)

1. **Shrestha, R.**, Benjamin, M.*, & Meyer, J. (2020). Pre-Exposure Prophylaxis (PrEP) for People Who Inject Drugs (PWID). In *'The Opioid Epidemic and Infectious Diseases* (pp. 223-236). Elsevier. doi: 10.1016/B978-0-323-68328-9.00011-4
2. **Shrestha, R.**, Karki, P.*, & Copenhaver, M. (2019). Addressing the Challenges of Neuro-cognitive Impairment (NCI) on Treatment Engagement. In *'The Wiley Handbook of Patient Engagement in Healthcare Treatment: Theory, Research and Clinical Practice* (pp. 109-140). Wiley. doi: 10.1002/9781119129530.ch6

Peer-Reviewed Publications (Accepted)

(*denotes current/former undergraduate/graduate student or mentee; † denotes collaborators)

3. **Shrestha, R.**, Fisher, C., Wickersham, J., Khati, A.*, Kim, R.*, Azwa, I., & Goldsamt, L. (2021). Privacy and Confidentiality Concerns Related to the Use of mHealth Apps for HIV Prevention Efforts Among Malaysian Men Who Have Sex with Men: Cross-sectional Survey Study. *JMIR Formative Research*. 5(12): e28311. doi: 10.2196/28311
4. GBD 2019 Chewing Tobacco Collaborators[†] (2021). Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet Public Health*. 6(7): e482-3499. doi: 10.1016/S2468-2667(21)00065-7
5. Sullivan, M.C.*, Mistler, C.*, Copenhaver, M.M., Wickersham, J.A., Ni, Z.*, Kim, R.S.*, & **Shrestha R.** (2021). Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder. *Health Psychology*. (In Press). doi: 10.1037/hea0001120
6. Xhou, X.*, Altice, F., Chandra, D.*, DiDomizio, L.*, Copenhaver, M., & **Shrestha, R.** (2021). Use of Pre-Exposure Prophylaxis Among People Who Inject Drugs: Exploratory

- Findings of the Interaction Between Race, Homelessness, and Trust. *AIDS & Behavior*. 25: 3743–3753. doi: 10.1007/s10461-021-03227-7
7. Mistler, C.*, **Shrestha, R.**, Gunstad, J., Sanborn, V., & Copenhaver, M. (2021). Adapting Intervention approaches for patients with opioid use disorder to accommodate their cognitive dysfunction. *General Psychiatry*. 34(4): e100412. doi: 10.1136/gpsych-2020-100412
 8. GBD 2019 Tobacco Collaborators[†] (2021). Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet*. 397(10292): 2337-2360. doi: 10.1016/S0140-6736(21)01169-7
 9. Bachireddy, C., **Shrestha, R.**, Azbel, L., Kurmanalieva, A., Shumskaia, N., Rozanova, J., Wegman, M., Meyer, J.M., & Altice, F.L. (2021). Methadone Within Prison and Linkage to and Retention in Care Upon Community Release for People with Opioid Use Disorder in Kyrgyzstan: Evaluation of a National Program. *International Journal of Drug Policy*. 101:103558. doi: 10.1016/j.drugpo.2021.103558
 10. Copenhaver, M. Sanborn, V., **Shrestha, R.**, Mistler, C.*, Sullivan, M.*, & Gunstad, J. (2021). Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. *Drug and Alcohol Dependence*. 224:108726. doi: 10.1016/j.drugalcdep.2021.108726
 11. Mistler, C.*, Sullivan, M.*, Copenhaver, M., Meyer, J.P., Roth, A.M., Sheno, S.V., Edelman, J.E., Wickersham, J., & **Shrestha, R.** (2021). Differential impacts of COVID-19 among racial-ethnic minorities with opioid use disorder. *Journal of Substance Abuse Treatment*. 129:108387. doi: 10.1016/j.jsat.2021.108387
 12. Tran, N.K., Van Der Pol, B., **Shrestha, R.**, Bazzi, A.R., Bellamy, S.L., Sherman, S.G., Roth, A.M. (2021). Limited risk compensation among women who inject drugs: results from the Project SHE PrEP Demonstration Study in Philadelphia. *Sexually Transmitted Diseases*. (In press). doi: 10.1097/OLQ.0000000000001577
 13. Mistler, C.*, Sullivan, M.*, Wickersham, J., Copenhaver, M., & **Shrestha, R.** (2021). Clinical and demographic correlates of willingness to use at-home testing measures for COVID-19 among opioid-dependent individuals. *Substance Abuse*. 43:1, 708-712, doi: 10.1080/08897077.2021.2007511
 14. Chandra, D.*, Altice, F., Copenhaver, M., DiDomizio, L.*, & **Shrestha, R.** (2021). Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People who Inject Drugs. *Substance Use and Misuse*. 56:7, 979-987, doi: 10.1080/10826084.2021.1901931
 15. Mistler, C.*, Curley, M. C., Rosen, O. A.*, El-Krab, R., Khati, A.*, Wickersham, J., Copenhaver, M., & **Shrestha, R.** (2021). The Impact of COVID-19 on Access to HIV

- Prevention Services among Opioid-Dependent Individuals. *Journal of Community Health*. 46, 960–966 (2021). doi: 10.1007/s10900-021-00979-0
16. Mistler, C.*, Rosen, A.*, Eger, W.*, Copenhaver, M., & **Shrestha, R.** (2021, Under review). Fentanyl Test Strip Use and Overdose History among Individuals with Opioid-Dependence. *Austin Journal of Public Health and Epidemiology*. 8(6): 1117. doi:
 17. **Shrestha, R.**, DiDomizio, L.*, Kim, R.*, Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Journal of Substance Use Treatment*. 117:108058. doi: 10.1016/j.jsat.2020.108058
 18. **Shrestha, R.**, Alias, H., Wong, L. P., Altice, F., & Lim, H. (2020). Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: Results from a conjoint-based analysis. *BMC Public Health*, 20 (1777). doi: 10.1186/s12889-020-09832-w
 19. Ni, Z.*, Altice, F., Copenhaver, M., DiDomizio, L.*, Wickersham, J., & **Shrestha, R.** (2020). Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. *Drug and Alcohol Dependence*. 219:108477. doi: 10.1016/j.drugalcdep.2020.108477
 20. Mistler, C.*, Copenhaver, M., & **Shrestha, R.** (2020). The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs (PWID): A systematic review. *AIDS & Behavior*. 25, 1490–1506. doi: 10.1007/s10461-020-02988-x
 21. **Shrestha, R.**, Galka, J.M., Azwa, I., Lim, H., Guadamuz, T. E., Altice, F., & Wickersham, J. (2020). Willingness to Use HIV Self-Testing and Associated Factors among Transgender Women in Malaysia. *Transgender Health*.5: 182-190. doi: 10.1089/trgh.2019.0085
 22. Ni, Z.*, Lebowitz, E.R., Zou, Z., Wang, H., Liu, H., Hu, J., Wu, J., Zhang, L., **Shrestha, R.**, & Altice, F. (2020). Response to the COVID-19 Outbreak in Urban Settings in China. *Journal of Urban Health*. 98, 41–52. doi: 10.1007/s11524-020-00498-8
 23. Copenhaver, M., Sanborn, V., **Shrestha, R.**, Mistler, C.*, & Gunstad, J. (2020). Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment. *Journal of Addictive Diseases*. 39(2):166-174. doi: 10.1080/10550887.2020.1831129
 24. Mistler, C.*, Chandra, D.*, Copenhaver, M., Wickersham, J., & **Shrestha, R.** (2020). Engagement in harm reduction strategies after suspected fentanyl contamination among opioid-dependent individuals. *Journal of Community Health*. 46, 349–357 (2021). doi: 10.1007/s10900-020-00928-3
 25. **Shrestha, R.**, Altice, F., DiDomizio, L.*, Sibilio, B., Ranjit, Y., & Copenhaver, M.

- (2020). Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. *Patient Preference and Adherence*, 14: 107-118. doi: 10.2147/PPA.S236794
26. Sanborn, V., Gunstad, J., **Shrestha, R.**, Mistler, C.*, & Copenhaver, M. (2020). Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. *Applied Neuropsychology: Adult*. (In press). doi: 10.1080/23279095.2020.1769099
 27. Ranjit, Y.S., **Shrestha, R.**, Copenhaver, M., Altice, F.L. (2020). Online HIV Information Seeking and Pre-Exposure Prophylaxis Awareness among People Who Use Drugs. *Journal of Substance Abuse Treatment*, 111: 16-22. doi: 10.1016/j.jsat.2019.12.010
 28. Galka, J., Wang, M., Azwa, I., Gibson, B., Lim, H., **Shrestha, R.**, & Wickersham, J. (2020). Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention and PrEP Implementation Preferences Among Transgender Women in Malaysia. *Transgender Health*. 5: 258-266. doi: 10.1089/trgh.2020.0003
 29. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation for Medication Adherence, Viral Suppression, and Adherence to Antiretroviral Therapy (ART) among HIV-Positive Drug Users. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 80(2):166-173. doi: 10.1097/QAI.0000000000001891
 30. **Shrestha, R.**, Lim, H.S., Altice, F. L., Copenhaver, M.M., Wickersham, J., Saifi, R., Halim, M.A., Naning, H., & Kamarulzaman, A. (2019). Use of Smartphone to Seek Sexual Health Information Online Among Malaysian Men Who Have Sex with Men (MSM): Implications for mHealth Intervention to increase HIV testing and reduce HIV risks. *Journal of Community Health*. 45(1):10-19. doi: 10.1007/s10900-019-00713-x
 31. **Shrestha, R.**, Altice, F., Sibilio, B., Ssenyonjo, J.*, & Copenhaver, M. (2019). Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHR-P-BB study. *Contemporary Clinical Trials*, 82: 77-84. doi: 10.1016/j.cct.2019.06.012
 32. Ssenyonjo, J.*, **Shrestha, R.**, & Copenhaver, M. (2019). Influence of Stigma on Pre-Exposure Prophylaxis (PrEP) Care Continuum Among Men and Transwomen Who Have Sex with Men (MTWSM) in the United States. *International Journal of HIV/AIDS Prevention, Education, and Behavioural Science*. 5: 134-140. doi: 10.11648/j.ijhpebs.20190502.18
 33. **Shrestha, R.** & Copenhaver, M. (2018). Viral Suppression among HIV-Infected Methadone-Maintained Patients: The Role of Ongoing Injection Drug Use and Adherence to Antiretroviral Therapy (ART). *Addictive Behaviors*, 85:88-93. doi: 10.1016/j.addbeh.2018.05.031
 34. **Shrestha, R.**, Altice, F., Karki, P.*, & Copenhaver, M. M. (2018). Integrated bio-

- behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: A pilot feasibility study. *AIDS & Behavior*, 22(8):2640-2649. doi: 10.1007/s10461-018-2099-0
35. **Shrestha, R.**, Altice, F., Sibilio, B., & Copenhaver, M. (2018). HIV Sero-Status Non-Disclosure among High-Risk Drug Users Living with HIV: The Roles of HIV-Related Stigma, Risk Behavior, and Social Support. *Journal of Community Health*, 44(1):112-120. doi: 10.1007/s10900-018-0560-7
 36. **Shrestha, R.**, & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users. *Frontiers in Public Health*, 6:195 doi: 10.3389/fpubh.2018.00195
 37. **Shrestha, R.**, Karki, P., Altice, F., Dubov, O., Fraenkel, L., Huedo-Medina, T., & Copenhaver, M. M. (2017). Measuring Acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: An application to primary HIV prevention among high-risk drug users. *AIDS & Behavior*, 22(4):1228-1238. doi: 10.1007/s10461-017-1851-1
 38. **Shrestha, R.**, Altice, F., Karki, P., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. *Frontiers in Immunology*, 8:561. doi: 10.3389/fimmu.2017.00561
 39. **Shrestha, R.**, Karki, P., Huedo-Medina, T., Altice, F., Meyer, J., Madden, L., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis and the likelihood of practicing safer drug- and sex-related risk behaviors among high-risk drug users in treatment. *Drug and Alcohol Dependence*, 173:107-116. doi: 10.1016/j.drugalcdep.2016.12.023
 40. Bazazi, A.R., Wickersham, J., Wegman, M, Pillai, V., Culbert, G., **Shrestha, R.**, Al-Darraj, H., Copenhaver, M., Kamarulzaman, A., & Altice, F.L. (2017). Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. *Contemporary Clinical Trials*, 59:1-12. doi: 10.1016/j.cct.2017.05.006
 41. **Shrestha, R.**, Karki, P., & Copenhaver, M. M. (2017). Interest in Use of mHealth Technology in HIV Prevention and Associated Factors among High-Risk Drug Users in Treatment. *AIDS Care*, 29(9):1144-1148. doi: 10.1080/09540121.2017.1325439
 42. **Shrestha, R.**, Weikum, D., Copenhaver, M., & Altice, F. (2017). A Self-report Measure to Detect Neurocognitive Impairment Among Incarcerated People Living with HIV in the Malaysian Context: an Exploratory Factor Analysis. *International Journal of Mental Health and Addiction*, 15(4):812-825. doi: 10.1007/s11469-017-9752-0

43. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. M. (2017). Intent to use pre-exposure prophylaxis (PrEP), HIV risk behaviors, and self-report neurocognitive symptoms among high-risk drug users: A mediation analysis. *Journal of the Association of Nurses in AIDS Care*, 28(4):612-621. doi: 10.1016/j.jana.2017.04.005
44. Weikum, D., **Shrestha, R.**, Ferro, E.G., Vagenas, P., Copenhaver, M., Spudich, S., Alpert, M.D., Cabello, R., Lama, J.R., Sanchez, J., & Altice, F. (2017). An Explanatory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among HIV-infected Men Who Have Sex with Men and Transgender Women in Peru. *AIDS Care*, 29(10):1297-1301. doi: 10.1080/09540121.2017.1322681
45. **Shrestha, R.**, Huedo-Medina, T., Krishnan, A., Altice, F., & Copenhaver, M. (2016). Examining the Acceptability of mHealth Technology in HIV Prevention among High-risk Drug Users in Treatment. *AIDS and Behavior*, 21(11): 3100-3110. doi: 10.1007/s10461-016-1637-x
46. **Shrestha, R.**, Copenhaver, M., Krishnan, A., Bazazi, A., & Altice, F. (2016). A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Quality of Life among Incarcerated HIV-Positive Malaysian Men with Opioid Dependence. *AIDS and Behavior*, 21(4): 1059-1069. doi: 10.1007/s10461-017-1693-x
47. **Shrestha, R.**, Huedo-Medina, T. B., Altice, F., Karki, P., & Copenhaver, M. M. (2016). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *AIDS and Behavior*, 21(5):1299-1308. doi: 10.1007/s10461-016-1650-0
48. **Shrestha, R.**, Weikum, D., Copenhaver, M., & Altice, F. (2016). The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *AIDS & Behavior*, 21(4):1070-1081. doi: 10.1007/s10461-016-1526-3.
49. **Shrestha, R.**, Karki, P., Huedo-Medina, T., & Copenhaver, M. (2016). Treatment engagement moderates the effect of neurocognitive impairment on antiretroviral therapy adherence among HIV-infected drug users in treatment. *Journal of the Association of Nurses in AIDS Care*, 28(1):85-94. doi: dx.doi.org/10.1016/j.jana.2016.09.007
50. Huedo-Medina, T. B., **Shrestha, R.**, & Copenhaver, M. M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users in Treatment. *AIDS & Behavior*, 20(8):1646-57. doi: 10.1007/s10461-016-1394-x
51. Copenhaver, M., **Shrestha, R.**, Wickersham, J. A., Weikum, D., & Altice, F. L. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. *Journal of Substance Abuse Treatment*, 63:61-65. doi: 10.1016/j.jsat.2016.01.002

52. **Shrestha, R.,** & Copenhaver, M. (2016). The Influence of Neurocognitive Impairment on HIV Risk Behaviors among High-Risk Drug Users: A Systematic Review. *Frontiers in Public Health*, 4:16. doi: 10.3389/fpubh.2016.00016
53. Karki, P., **Shrestha, R.,** Huedo-Medina, T., & Copenhaver, M. (2016). The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: A systematic review. *Evidence-based Medicine and Public Health*, 2(e1229):1-6. doi: 10.14800/emph.1229
54. **Shrestha, R.,** Karki, P., & Copenhaver, M. (2016). Use of Commercial Sex Workers among Men in Nepal: Prevalence, STIs/HIV-related Risk Behaviors, and Gender Ideology. *Primary Prevention Insights*, 6:11-17. doi: <http://dx.doi.org/10.4137/PPRI.S39664>
55. **Shrestha, R.,** & Copenhaver, M. (2016). Association between Intimate Partner Violence against Women and HIV Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Violence Against Women*. 22(13):1621-1641. doi: 10.1177/1077801216628690
56. **Shrestha, R.,** Karki, P., Pandey, S., & Copenhaver, M. (2016). Adapting an Evidence-Based HIV Prevention Intervention Targeting High-Risk Migrant Workers: The Process and Outcome of Formative Research. *Frontiers in Public Health*, 4:61. doi: 10.3389/fpubh.2016.00061
57. **Shrestha, R.,** Huedo-Medina, T. B., & Copenhaver, M. M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. *Substance Abuse: Research and Treatment*, 9:17-24. doi: 10.4137/SART.S23332
58. **Shrestha, R.,** Krishnan, A., Altice, F., & Copenhaver, M. (2015). A Non-Inferiority Trial of an Evidence-Based Secondary HIV Prevention Behavioral Intervention Compared to an Adapted, Abbreviated Version: Rationale and Intervention Description. *Contemporary Clinical Trials*, 44:95-102. doi: 10.1016/j.cct.2015.08.002
59. **Shrestha, R.,** Karki, P., & Copenhaver, M. (2015). Early sexual debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Journal of Community Health*, 41(1):70-77. doi: 10.1007/s10900-015-0065-6
60. **Shrestha, R.,** & Copenhaver, M. (2015). Long-Term Effects of Childhood Risk Factors on Cardiovascular Health during Adulthood. *Clinical Medicine Reviews in Vascular Health*, 7:1-5. 10.4137/CMRVH.S29964.
61. **Shrestha, R.,** Karki, P., Suwal, A. & Copenhaver, M. (2015). Sex Trafficking Related Knowledge, Awareness, and Attitudes Among Adolescent Female Students in Nepal: A Cross-Sectional Study. *PLoS ONE*, 10(7): e0133508. doi: 10.1371/journal.pone.0133508

62. Baldwin, P., **Shrestha, R.**, Potrepka, J., & Copenhaver, M. (2013). The Age of Initiation of Drug Use and Sexual Behavior May Influence Subsequent HIV Risk Behavior: A Systematic Review. *ISRN AIDS*, 2013:976035. doi: 10.1155/2013/976035
63. **Shrestha, R.** (2012). Maternal Mortality in Nepal: Addressing the Issue. *International Journal of Health Sciences Research*, 2(9):65-74.
64. **Shrestha, R.** (2012). Arsenic Contamination of Groundwater in Nepal: Good Public Health Intention Gone Bad. *Inquiries Journal/Student Pulse*, 4(09).

Manuscripts (Under Review & In Preparation)

(*denotes current/former undergraduate/graduate student or mentee)

1. **Shrestha, R.**, Meyer, J., Shenoi, S., & Wickersham, J. (2021, Revision submitted). COVID-19 vaccine hesitancy and associated factors among people with HIV in the United States: findings from a national survey. *Vaccines*.
2. Gunstad, J., Sanborn, V., **Shrestha, R.**, Mistler, C.*, & Copenhaver, M. (2021, Revision submitted). Cluster Analysis of Data from the Brief Inventory of Neurocognitive Impairment (BINI) to Develop Neuro-Cognitive Profiles Among Opioid-Dependent Patients in Drug Treatment. *Journal of Addictive Diseases*.
3. **Shrestha, R.**, Altice, F., DiDomizio, L.*, Mistler, C.*, Khati, A.*, Zhou, X.*, & Wickersham, J. (2021, Under review). Examining the Acceptability of mHealth Technology in HIV Prevention among men who have sex with men in Malaysia. *JMIR Public Health and Surveillance*.
4. Eger, W.*, Adaralegbe, A., Khati, A.*, Azwa, I., Wickersham, J., Osborne, S.*, & **Shrestha, R.** (2021, Under review). Correlates of Preexposure Prophylaxis (PrEP) Use among Men Who Have Sex with Men (MSM) in Malaysia. *International Journal of STD & AIDS*.
5. Pederson, C.J.*, Wickersham, J., Khoshnood, K., Gibson, B.A., Kamarulzaman, A., Altice, F.L., & **Shrestha, R.** (2021, Under review). Prevalence and Correlates of Active Amphetamine-type Stimulants (ATS) Use Among Female Sex Workers in Malaysia. *Frontiers in Psychiatry*.
6. Kim, R.*, Wickersham, J., Azwa, I., Galka, J., & **Shrestha, R.** (2021, Under review). Willingness to Use HIV Self-Testing (HIVST) for HIV prevention among Female Sex Workers in Malaysia. *AIDS Care*.
7. Wickersham, J., Meyer, J., Shenoi, S., & **Shrestha, R.** (2021, Under review). Willingness to be vaccinated for COVID-19 among people with HIV in the United States: results from a national survey. *Frontiers in Medicine*.
8. Lim, H.S., Alias, H., Wong, L. P., Wickersham, J., & **Shrestha, R.** (2021, Under review).

- A Study of Willingness to Use HIV Self-Testing (HIVST) among Men Who Have Sex with Men and Transgender Women in Malaysia. *PloS One*.
9. Kim, L.*, Azwa, I., **Shrestha, R.**, Xiang, N.G., Lim, W.C., Kamarulzaman, A., & Wickersham, J. (2021, In Preparation). Drivers of HIV viral suppression among recently diagnosed HIV+ men who have sex with men in Kuala Lumpur, Malaysia.
 10. DiDomizio, L.*, Copenhaver, M., Altice, F., Wickersham, J., & **Shrestha, R.** (2021, In Preparation). Correlates of non-fatal overdose among opioid-dependent people who inject drugs.
 11. Lee, J., Wickersham, J.A., Morozova, O., Azwa, I., **Shrestha, R.**, Lim, H.S., Gibson, B. (2021, In Preparation). Drivers of active syphilis infection in cisgender and transgender women sex workers in Malaysia.
 12. DiDomizio, L.*, **Shrestha, R.**, Galka, J., & Wickersham, J. (2021, In Preparation). Correlates of Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV prevention among Female Sex Workers in Malaysia.
 13. Huedo-Medina, T., **Shrestha, R.**, Altice, F., Mistler, C.*, & Copenhaver, M. (2021, In Preparation). A randomized controlled trial of the Holistic Health for HIV (3H+) intervention among high-risk HIV-infected opioid-dependent drug users.
 14. Ni, Z.*, **Shrestha, R.**, Altice, F., & Wickersham, J.A. (2021, In Preparation). Evaluating Physicians' Intention to Discriminate Against Men Who Have Sex with Men in Malaysia.
 15. Wickersham, J.A., Lim, H.S., Akbar, M.*, McStea, **Shrestha, R.**, M., Lim, J., Kamarulzaman, A., & Altice, F.L. (2021, In Preparation). Concurrency between condomless anal sex and amphetamine use in men who have sex with men.
 16. Deng, Y., **Shrestha, R.**, Altice, F., & Copenhaver, M. (2021, In Preparation). Estimation of cost-effectiveness of secondary HIV prevention intervention (Holistic Health for HIV) for HIV-infected opioid-dependent drug users in the United States.

CONFERENCE PAPERS

Oral Presentations

1. Mistler, C.*, Sullivan, M., Copenhaver, M., Meyer, J.P., Roth, A.M., Shenoi, S.V., Edelman, J.E., Wickersham, J., & **Shrestha, R.** (2021). Racial and Ethnic Differences in the Impacts of COVID-19 Pandemic Among People with Opioid Use Disorder. *Oral presentation at the International AIDS Society COVID-19 Conference*. Virtual Meeting.
2. Kim, R.*, Wickersham, J., & **Shrestha, R.** (2021). Willingness to use HIV Self-Testing Among Female Sex Workers in Malaysia. *Oral presentation at the 42nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.

3. Mistler, C.*, Sullivan, M., Copenhaver, M., Meyer, J.P., Roth, A.M., Shenoi, S.V., Edelman, J.E., Wickersham, J., & **Shrestha, R.** (2021). Racial and Ethnic Differences in the Impacts of COVID-19 Pandemic Among People with Opioid Use Disorder. *Oral presentation at the 42nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
4. Ni, Z.*, Altice, F., Copenhaver, M. M., Wickersham, J. A., DiDomizio, E., Nelson, L., & **Shrestha, R.** (2021). Willingness to Initiate Pre-Exposure Prophylaxis (PrEP) and Its Use among Opioid-Dependent Individuals in Drug Treatment. *Oral presentation at the 42nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
5. Sullivan, M. C., Mistler, C. B.*, Copenhaver, M. M., Wickersham, J. A., Ni, Z.*, Kim, R.*, & **Shrestha, R.** (2021). Racial differences in willingness to vaccinate against COVID-19 in people with Opioid Use Disorder. *Oral presentation at the 42nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
6. Mistler, C.*, Chandra, D., Copenhaver, M., Wickersham, J., & **Shrestha, R.** (2021). Engagement in harm reduction strategies after suspected fentanyl contamination among opioid-dependent individuals. *Oral presentation at the 42nd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
7. **Shrestha, R.**, DiDomizio, E.*, Kim, R.*, Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and willingness to use long-acting injectable PrEP (LAIP) among people who inject drugs. *Oral presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
8. Mistler, C.*, Copenhaver, M., & **Shrestha, R.** (2020). The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. *Oral presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
9. Rankin, R.*, Akbar, M., Azwa, I., Li, M., Lo, Y.R., **Shrestha, R.**, Wickersham, J.A. (2020). Is risk compensation real? The effect of perceived level of HIV transmission risk on risk behavior in an open-label pilot PrEP-based intervention in men who have sex with men in Malaysia. *Oral presentation at the Asia-Pacific AIDS & Co-Infections Conference*. Bangkok, Thailand.
10. Chandra, D., Altice, F., Copenhaver, M., DiDomizio, E.*, Zhou, X., & **Shrestha, R.** (2020). Intentional fentanyl drug use and associated factors among opioid-dependent people who inject drugs (PWID). *Oral presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
11. **Shrestha, R.**, DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Oral presentation at the Annual Conference of the*

College on Problems of Drug Dependence (CPDD). Hollywood, Florida.

12. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Preliminary Evidence for Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis (PrEP) among Drug Users. *Accepted for oral presentation at the 2019 National HIV Prevention Conference (NHPC)*. Georgia, USA.
13. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation to Adhere to Medication, and ART Adherence among HIV-Positive Methadone-Maintained Patient. *Oral presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
14. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users in Treatment. *Roundtable presentation at the 146th American Public Health Association (APHA) Conference*. San Diego, California.
15. **Shrestha, R.**, Altice, F., Karki, P., & Copenhaver, M. (2018). Integrated biobehavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. *Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. New Orleans, Louisiana.
16. **Shrestha, R.**, & Copenhaver, M. (2018). Experiences Using Pre-Exposure Prophylaxis for HIV Prevention among High-Risk Drug Users. *Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. New Orleans, Louisiana.
17. **Shrestha, R.**, Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *Oral presentation at the 145th American Public Health Association (APHA) Conference*. Atlanta, Georgia.
18. **Shrestha, R.**, Altice, F., Karki, P., & Copenhaver, M. (2017). Developing an Integrated, Brief Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. *Oral presentation at the 145th American Public Health Association (APHA) Conference*. Atlanta, Georgia.
19. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. *Oral presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.
20. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Feasibility, Acceptability, and Preliminary Efficacy of an Integrated Bio-Behavioral Approach for Adherence to

- Pre-Exposure Prophylaxis (PrEP) and HIV Risk Reduction among High-Risk Drug Users. *Oral presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
21. **Shrestha, R.**, Karki, P., Copenhaver, M., & Altice, F. (2016). Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Oral presentation at the 2016 Connecticut Public Health Association Annual Conference*. New Haven, Connecticut.
 22. **Shrestha, R.**, Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
 23. **Shrestha, R.**, Weikum, D., Copenhaver, M., & Altice, F. (2016). Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
 24. **Shrestha, R.**, Copenhaver, M., & Altice, F. (2016). A moderated mediating model of stigma, depression, and social support on quality of life among incarcerated, HIV-positive men with opioid dependence in Malaysia. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
 25. Karki, P., **Shrestha, R.**, & Copenhaver, M. (2016). The Use of Female Sex Workers among Men in Nepal: Prevalence, STIs/HIV-Related Risk Behaviors, and Gender Ideology. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
 26. Ahmed, T., **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2016). Self-efficacy mediates the effect of neurocognitive impairment on HIV risk reduction intervention outcomes among high-risk drug users in treatment. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
 27. **Shrestha, R.**, & Copenhaver, M. (2015). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Oral presentation at the 143rd American Public Health Association (APHA) Conference*. Chicago, IL.
 28. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2015). Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Oral presentation at the 3rd International Conference on HIV/AIDS, STDs & STIs*. Atlanta, GA.
 29. **Shrestha, R.**, & Copenhaver, M. (2014). Association between Intimate Partner Violence

against Women and HIV Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Oral presentation at the 2014 CHOP Global Health Conference*. Philadelphia, PA.

30. **Shrestha, R.**, & Copenhaver, M. (2013). HIV-Related Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Oral presentation at the 141st American Public Health Association (APHA) Conference*. Boston, MA.

Poster Presentations

1. **Shrestha, R.**, Meyer, J., Shenoi, S., & Wickersham, J. (2021). COVID-19 vaccine hesitancy and associated factors among people with HIV in the United States: findings from a national survey. *E-poster presentation at the 11th International AIDS Conference on HIV Science*. Berlin, Germany.
2. Kim, R., Wickersham, J., Azwa, I., Galka, J., & **Shrestha, R.** (2021). Willingness to use HIV self-testing among female sex workers in Malaysia. *E-poster presentation at the 11th International AIDS Conference on HIV Science*. Berlin, Germany.
3. Wickersham, J., Meyer, J., Shenoi, S., & **Shrestha, R.** (2021). Willingness to be vaccinated for COVID-19 among people with HIV in the United States: results from a national survey. *E-poster presentation at the 11th International AIDS Conference on HIV Science*. Berlin, Germany.
4. Mistler, C., Curley, M. C., Rosen, O. A., El-Krab, R., Khati, A., Wickersham, J., Copenhaver, M., & **Shrestha, R.** (2021). The impact of COVID-19 on access to HIV prevention services among people who inject drugs. *E-poster presentation at the 11th International AIDS Conference on HIV Science*. Berlin, Germany.
5. Copenhaver, M. Sanborn, V., **Shrestha, R.**, Mistler, C., Sullivan, M.*, & Gunstad, J. (2021). Developing a cognitive dysfunction risk score for people who inject drugs in drug treatment. *E-poster presentation at the 11th International AIDS Conference on HIV Science*. Berlin, Germany.
6. Pajarillo, C., Azwa, I., Akbar, M., Li, M., Lo, Y.R., **Shrestha, R.**, Wickersham, J.A. (2020). Occurrence of sexually transmitted infections in men who have sex with men receiving pre-exposure prophylaxis (PrEP) for HIV prevention: Results from Malaysia's first PrEP demonstration study. *Poster presentation at the Asia-Pacific AIDS & Co-Infections Conference*. Bangkok, Thailand.
7. **Shrestha, R.**, DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Poster presentation at the 12th International Women's and Children's Health and Gender (InWomen's) Group conference*. Hollywood, Florida.
8. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV Testing Practices and Reasons

- for Never-Testing among Men Who Have Sex with Men (MSM) in Malaysia. *Poster presentation at the 10th IAS Conference on HIV Science (IAS 2019)*. Mexico City, Mexico.
9. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Preferences for long-acting injectable (LAI) versus daily oral pre-exposure prophylaxis (PrEP) among high-risk drug users. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
 10. **Shrestha, R.**, Ahmad, A., & Altice, F. (2019). Impact of Methadone Dose on Post-Release Linkage to Treatment among Incarcerated HIV-Infected Individuals Transitioning to the Community in Malaysia. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
 11. Ranjit, Y., **Shrestha, R.**, Copenhaver, M., & Altice, F. (2019). Online Information Seeking and Pre-Exposure Prophylaxis awareness among Drug Users Without HIV. *Poster presentation at the National Communication Association (NCA) 105th Annual Convention*. Baltimore, Maryland.
 12. Teti, M., Robinson, E., Landes, D., Pichon, L., & **Shrestha, R.** (2019). “Who? What? Is that a test?” African Americans in non-metropolitan Midwestern US identify knowledge gaps and opportunities for PrEP for HIV prevention. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
 13. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Antiretroviral Therapy (ART) Adherence among HIV-Infected Opioid-Dependent Patients: The Role of HIV-Related Stigma and Motivation to Adhere to ART. *Poster presentation at the 2019 National HIV Prevention Conference (NHPC)*. Georgia, USA.
 14. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Use of Smartphone to Find Sexual Health Information Online Among Malaysian MSM: Implications for mHealth Intervention. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
 15. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis among Drug Users. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
 16. **Shrestha, R.**, Ni, Z., Copenhaver, M., Altice, F., & Lim, S. (2019). HIV testing practices and reasons for never-testing among men who have sex with men (MSM) in Malaysia. *Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD)*. San Antonio, TX.
 17. **Shrestha, R.**, Altice, F., Ssenyonjo, J., Sibilio, B., & Copenhaver, M. (2019). Testing an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis

- and HIV risk reduction among methadone-maintained patients: The CHRP-BB study. *Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD)*. San Antonio, TX.
18. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Opioid-Dependent Women in Violent Relationship Are More Likely to Show Sub-Optimal Adherence to Pre-Exposure Prophylaxis (PrEP): Implications for Primary HIV Prevention. *Poster presentation at the 11th International Women's and Children's Health and Gender (InWomen's) Group Conference*. San Antonio, TX.
 19. Ssenyonjo, J., **Shrestha, R.**, & Copenhaver, M. (2019). Stigma May Influence Willingness and Uptake of Pre-Exposure Prophylaxis (PrEP) in High-risk Populations. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
 20. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence among HIV-Positive Methadone-Maintained Patients. *Poster presentation at the 9th International Conference on Stigma*. Washington, DC, USA.
 21. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). HIV-related stigma, motivation to adhere to ART, and ART adherence among HIV-infected methadone-maintained patients. *Poster presentation at the HIV Drug Therapy Glasgow 2018*. Glasgow, UK.
 22. **Shrestha, R.** & Copenhaver, M. (2018). Viral Suppression among HIV+ Methadone-Maintained Patients: The Role of Ongoing Injection Drug Use and Adherence to Antiretroviral Therapy. *Poster presentation at the 20th Annual International Meeting of the Institute of Human Virology*. Baltimore, MD.
 23. **Shrestha, R.** & Copenhaver, M. (2018). HIV Risk, and Awareness and Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Female Drug Users. *Poster presentation at the Ending Gender Inequalities: Evidence to Impact Conference*. Johannesburg, South Africa.
 24. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Female Drug Users in Treatment. *Poster presentation at the Ending Gender Inequalities: Evidence to Impact Conference*. Johannesburg, South Africa.
 25. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). Serostatus Non-Disclosure to Sexual Partners among High-Risk Drug Users Living with HIV: Examining the Roles of HIV-Related Stigma and Risk Behavior. *Poster presentation at the 22nd International AIDS Conference*. Amsterdam, Netherlands.
 26. Bachireddy, C., **Shrestha, R.**, Azbel, L., Kurmanalieva, A., Shumskaiya, N., Rozanova, J., Meyer, J.P., & Altice, F. (2018). Methadone maintenance therapy uptake, retention, and

- linkage for people who inject drugs transitioning from prison to the community in Kyrgyzstan: Evaluation of a national program. *Poster presentation at the 22nd International AIDS Conference*. Amsterdam, Netherlands.
27. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users in Treatment. *Poster presentation at the 22nd International AIDS Conference (AIDS 2018)*. Amsterdam, Netherlands.
 28. **Shrestha, R.** & Copenhaver, M. (2018). Perceived HIV Risk Mediates the Relationship Between HIV Risk Behavior & Willingness to Use Pre-Exposure Prophylaxis among Drug Users. *Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
 29. Ssenyonjo, J., **Shrestha, R.**, & Copenhaver, M. (2018). Stigma May Influence Willingness and Uptake of Pre-Exposure Prophylaxis (PrEP) Among High-risk Populations. *Poster presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
 30. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Using conjoint analysis to measure the Acceptability of pre-exposure prophylaxis (PrEP) use for HIV prevention among high-risk drug users in treatment. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
 31. **Shrestha, R.**, Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
 32. **Shrestha, R.**, Altice, F., Karki, P., Huedo-Medina, T., & Copenhaver, M. (2017). Feasibility, Acceptability, and preliminary efficacy of the Bio-Behavioral Community-friendly Health Recovery Program (CHRP-BB): A combination approach for primary HIV prevention among high-risk drug users. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
 33. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2017). Examining the Acceptability of mHealth Technology in HIV Prevention among High-risk Drug Users in Treatment. *Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.
 34. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Intervention for High-Risk Drug Users: Taking into Account the Impact of Neurocognitive Impairment. *Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.
 35. Karki, P., **Shrestha, R.**, Altice, F., Huedo-Medina, T., & Copenhaver, M. (2017).

- Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. *Poster presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
36. **Shrestha, R.**, Karki, P., Copenhaver, M., & Altice, F. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Poster presentation at the HIV Drug Therapy Glasgow*. Glasgow, UK.
 37. **Shrestha, R.**, Karki, P., Huedo-Medina, T., & Copenhaver, M. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Poster presentation at the 18th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV*. New York, NY.
 38. **Shrestha, R.**, Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Palm Springs, California.
 39. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Palm Springs, California.
 40. **Shrestha, R.**, & Copenhaver, M. (2016). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Poster presentation at the Ending Gender Inequalities: Addressing the Nexus of HIV, Drug Use, and Violence with Evidence-based Action conference*. Chapel Hill, NC.
 41. **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. *Poster presentation at the 143rd American Public Health Association (APHA) Conference*. Chicago, IL.
 42. **Shrestha, R.**, & Copenhaver, M. (2015). Gender Differences in Associations between Neurocognitive Impairment and Cocaine Use among High-Risk Cocaine-Dependent Methadone-Maintained Patients. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Phoenix, Arizona.
 43. **Shrestha, R.**, & Copenhaver, M. (2014). Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Poster presentation at the 2015 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.

44. **Shrestha, R.**, & Copenhaver, M. (2014). Developing an Evidence-Based Intervention Targeting High-Risk Migrant Workers. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Juan, Puerto Rico.
45. **Shrestha, R.**, & Copenhaver, M. (2014). Gender-Related Differences in Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Program. *Poster presentation at the 2014 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.
46. **Shrestha, R.**, & Copenhaver, M. (2013). HIV Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
47. Copenhaver, M., Altice, F., & **Shrestha, R.** (2013). Using a Non-Inferiority Trial Approach to Test the Holistic Health for HIV (3H+) Intervention among HIV+ Drug Users. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
48. **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2013). HIV-Related Risk Behaviors among Migrant and Non-Migrant Workers in Nepal. *Poster presentation delivered at the Health, Workplace, and Environment: Cultivating Connections Conference*. Storrs, Connecticut.
49. **Shrestha, R.**, & Copenhaver, M. (2013). Understanding HIV-Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Poster presentation at the 2013 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.
50. **Shrestha, R.**, & Joshi, J. (2011). Characterizing Staurosporine Induced Cell Death in Various Cell Lines. *Poster presentation at the North East Alliance (NEA) Summer Research Program*. Storrs, Connecticut.
51. **Shrestha, R.**, & Joshi, J. (2010). Mechanistic Differences of Silica and Staurosporine Induced Death in MH-S Alveolar Macrophages and HeLa Cells. *Poster presentation at the North East Alliance (NEA) Summer Research Program*. Storrs, Connecticut.

Invited Talks/Presentations

1. **Shrestha, R.** (2022). Guest speaker (for Dr. Copenhaver, AHS). Development of “JomPrEP App”: mHealth Platform to Improve HIV Prevention Cascade in Malaysia. University of Connecticut.
2. **Shrestha, R.** (2021). Methods in Implementation Science: Nominal Group Technique. *Summer Bootcamp: Real-Life Implementation Science*. University of Malaya and Yale University.
3. **Shrestha, R.** (2021). Guest speaker (for Dr. Copenhaver, AHS). mHealth Interventions

- for HIV Prevention: A Case Example from Malaysia. University of Connecticut.
4. **Shrestha, R.** (Fall 2021). Guest speaker (for Dr. Eckert, AHS). Public Health: A Career for a Lifetime. University of Connecticut.
 5. **Shrestha, R.** (2021). Confidentiality, Privacy, and Data Security in mHealth Research. *HIV and Drug Abuse Prevention Research Ethics Training Institute (RETI)*. Fordham University.
 6. **Shrestha, R.** (2021). Telehealth in HIV Prevention and Care: Research Landscape. *CIRA: New England HIV Implementation Science Network*. Yale University.
 7. **Shrestha, R.** (2021). Access to Care and Ethical Issues in the Use of mHealth for HIV Prevention in LMICs: A Case Example from Malaysia. *Webinar: UConn Center for mHealth and Social Medica*. University of Connecticut.
 8. **Shrestha, R.** (2021). Mobile Technologies for HIV Prevention: Ethical Challenges & Future Directions. *Advancing Health & Social Justice: Spring 2021 Online Discussion Series: mHealth, Access to Care, & Ethics in the Age of COVID-19*. Fordham University.
 9. **Shrestha, R.** (2021). Guest speaker (for Dr. Copenhaver, AHS). Multipronged Approach to Implement mHealth for HIV Prevention: A Case Example from Malaysia. University of Connecticut.
 10. **Shrestha, R.** (Spring 2021). Guest speaker (for Dr. Eckert, AHS). Public Health: A Career for a Lifetime. University of Connecticut.
 11. **Shrestha, R.** (Spring ZXCVB. 5ED2021). Guest speaker (for Dr. Kaliszewski, AHS). Public Health: A Career for a Lifetime. University of Connecticut.
 12. **Shrestha, R.** (2020). Mobile Technologies for HIV Prevention: Using mHealth to Enhance PrEP Care Continuum among MSM in Malaysia. *ID/Rheum Research Conference*. Yale University.
 13. **Shrestha, R.** (2020). Guest speaker (for Dr. Copenhaver, AHS). mHealth for HIV prevention among key populations in Malaysia. University of Connecticut.
 14. **Shrestha, R.** (2019). mHealth-Based Approach: A Potential Platform to Enhance PrEP Care Continuum among Malaysian MSM. *Yale Clinical and Community Research Seminar Series*. Yale University.
 15. **Shrestha, R.** (2019). Guest speaker (for Dr. Copenhaver, AHS). Mobile Technologies for HIV Prevention: Using mHealth to Enhance PrEP Care Continuum among MSM in Malaysia. University of Connecticut.
 16. **Shrestha, R.** (2018). Developing and Testing a Brief, Integrated Bio-Behavioral HIV

- Prevention Intervention for High-Risk Drug Users. *CIRA Clinical and Health Services Research Core Meeting*. Yale University.
17. **Shrestha, R.** (2018). Exploring the use of pre-exposure prophylaxis for HIV prevention among high-risk drug users in treatment. *Yale Clinical and Community Research Seminar Series*. Yale University.
 18. **Shrestha, R.** (2018). Guest speaker (for Dr. Copenhaver, AHS). Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. University of Connecticut.
 19. **Shrestha, R.** (2017). Guest speaker (for Dr. Copenhaver, AHS). Developing & Testing a Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users. University of Connecticut
 20. **Shrestha, R.** (2016). Influence of Neurocognitive Impairment, Depression, & Alcohol Use Disorders on Quality of Life among Incarcerated, HIV+ Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *Yale Clinical and Community Research Seminar Series*. Yale University.
 21. **Shrestha, R.** (2016). Guest speaker (for Dr. Copenhaver, AHS). HIV-Risk Reduction Intervention and Neurocognitive Impairment. University of Connecticut.
 22. **Shrestha, R.** (2015). Guest speaker (for Dr. Copenhaver, AHS). The Influence of Neurocognitive Impairment on HIV Risk Reduction Intervention Outcomes. University of Connecticut.
 23. **Shrestha, R., & Clark, I.** (2012). National Committee for Quality Assurance Patient-Centered Medical Home Accreditation of United Communities and Family Services Edward and Mary Lord Family Health Center. *Community Health Center Association of Connecticut Meeting*. Connecticut.

TEACHING EXPERIENCE

- Spring 2017 **Teaching Assistant**, Biostatistics for Health Professions (Undergraduate-level course, 3 Credits)
Department of Allied Health Sciences, University of Connecticut
- Fall 2016 **Teaching Assistant**, Critical Issues in Health Promotion, Disease, & Disability Prevention (Graduate-level course, 3 Credits)
Department of Allied Health Sciences, University of Connecticut
- Spring 2016 **Instructor**, Writing Allied Health Research (Graduate-level course, 1 Credit)
Department of Allied Health Sciences, University of Connecticut
- Teaching Assistant**, Research for the Health Professionals (Graduate-level

course, 3 Credits)
Department of Allied Health Sciences, University of Connecticut

Fall 2015 **Instructor**, Writing Allied Health Research (Graduate-level course, 1 Credit)
Department of Allied Health Sciences, University of Connecticut

Teaching Assistant, Research for the Health Professionals (Graduate-level course, 3 Credits)
Department of Allied Health Sciences, University of Connecticut

Spring 2015 **Teaching Assistant**, Health Education & Behavioral Interventions for At-risk Populations (Graduate-level course, 3 Credits)
Department of Allied Health Sciences, University of Connecticut

TEACHING/MENTORSHIP DEVELOPMENT

Antoine Khati, Graduate Student, UConn

Sydney Osborne, Undergraduate Student (Honors), UConn

Jerome James, Undergraduate Student (Honors), UConn

Monique Kern, Undergraduate Student, UConn

Jessica Lee, Postgraduate Associate, Yale University

Rayne Kim, Postgraduate Associate, Yale University

William Eger, Postgraduate Associate, Yale University

Philip Tamburrino, Postgraduate Associate, Yale University

Jeffrey Lucas, PhD student, University of Philippines, Philippines

Patrice Hubert, PhD student, UConn [Primary mentor: Valerie Duffy]

Colleen Mistler, PhD student, UConn [Primary mentor: Michael Copenhaver]

Jude Ssenyonjo, PhD student, UConn [Primary mentor: Michael Copenhaver]

Aviana Rosen, PhD student, UConn [Primary mentor: Tania B. Huedo-Medina]

Zhao Ni, Post-doc, Yale University [Primary mentor: Frederick Altice]

Libby Didomizio, Postgraduate Associate, Yale University [Primary mentor: Frederick Altice]

Divya Chandra, Postgraduate Associate, Yale University [Primary mentor: Frederick Altice]

PRESS COVERAGE

1. UConn Today (August 16th, 2021): Quantifying Risk of Cognitive Dysfunction Among People in Drug Treatment Programs.
2. Open Access Government (April 28th, 2021): How is COVID Impacting Racial Minorities with Opioid Use Disorder?
3. UConn Today (April 26th, 2021): Impact of COVID-19 on Racial-Ethnic Minorities Among Persons with Opioid Use Disorder.
4. ContagionLive (July 12th, 2019): Trial Pairs PrEP with Behavioral Intervention to

Prevent HIV in Drug Users.

5. Infectious Disease Advisor (July 9th, 2018): Reduced HIV Viral Suppression Among Methadone-Maintained Patients.
6. AIDSFree Prevention Update (June 6th, 2016): Behavioral Prevention.